Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma

doi:10.3748/wjg.v30.i43.4620

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 43

This Article

(123)

(128)

(0)

(12)

(3873)

(9)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Nov 21, 2024; 30(43): 4620-4635
Published online Nov 21, 2024. doi: 10.3748/wjg.v30.i43.4620

Table 2 Summary of the best responses, n (%)

Variable	RECIST 11			mRECIST
Variable	BeSiIT (n = 28)	LeSiIT (n = 50)	P value	BeSiIT (n = 28)	LeSiIT (n = 50)	P value
CR	0 (0.0)	0 (0.0)	-	8 (28.6)	4 (8.0)	0.016^a
PR	17 (60.7)	23 (46.0)	0.212	9 (32.1)	25 (50.0)	0.127
SD	5 (17.9)	7 (14.0)	0.651	5 (17.9)	5 (1.0)	0.319
PD	6 (21.4)	20 (40.0)	0.095	6 (21.4)	16 (32.0)	0.320
ORR	17 (60.7)	23 (46.0)	0.791	17 (60.7)	29 (58.0)	0.815
DCR	22 (78.6)	30 (60.0)	0.095	22 (78.6)	34 (68.0)	0.320

^aP value < 0.05, and it is statistically significant.

RECIST: Response Evaluation Criteria in Solid Tumors; mRECIST: Modified Response Evaluation Criteria in Solid Tumors; BeSiIT: Bevacizumab plus sintilimab plus interventional treatment; LeSiIT: Lenvatinib plus sintilimab plus interventional treatment; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.

Full Size Table

Citation: Han RY, Gan LJ, Lang MR, Ren SH, Liu DM, Li GT, Liu YY, Tian XD, Zhu KW, Sun LY, Chen L, Song TQ. Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma. World J Gastroenterol 2024; 30(43): 4620-4635
URL: https://www.wjgnet.com/1007-9327/full/v30/i43/4620.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i43.4620

Han RY, Gan LJ, Lang MR, Ren SH, Liu DM, Li GT, Liu YY, Tian XD, Zhu KW, Sun LY, Chen L, Song TQ. Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma. World J Gastroenterol 2024; 30(43): 4620-4635 [PMID: 39575400 DOI: 10.3748/wjg.v30.i43.4620]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.